Please login to the form below

Not currently logged in

CDK4/6 inhibitors

This page shows the latest CDK4/6 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Kisqali combination follows Verzenio onto Cancer Drugs Fund

The ruling is good news for the company, which is vying with two other treatments in the same CDK4/6 inhibitors class, Eli Lilly’s Verzenio and market leader, Pfizer’s

Latest news

  • Lilly's abemaciclib data leaves potential uncertain Lilly's abemaciclib data leaves potential uncertain

    The trial also threw out some data that could have a bearing on all CDK4/6 inhibitors, namely that around one-third of women may not need a CDK 4/6 ... That view was echoed by Giuseppe Curigliano of the European Institute of Oncology (IEO) in Milan, Italy

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...